US Bancorp DE Buys 734 Shares of Avantor, Inc. (NYSE:AVTR)

US Bancorp DE boosted its stake in Avantor, Inc. (NYSE:AVTR) by 6.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,615 shares of the company’s stock after purchasing an additional 734 shares during the period. US Bancorp DE’s holdings in Avantor were worth $326,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in AVTR. Versant Capital Management Inc raised its stake in Avantor by 2,003.6% during the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after buying an additional 1,102 shares during the last quarter. Blue Trust Inc. raised its stake in Avantor by 1,830.3% during the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after buying an additional 1,391 shares during the last quarter. UMB Bank n.a. bought a new position in Avantor during the third quarter worth $49,000. Nisa Investment Advisors LLC raised its stake in Avantor by 69.6% during the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after buying an additional 835 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in Avantor by 89.9% during the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after buying an additional 1,285 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Avantor Trading Down 2.2 %

Shares of NYSE AVTR opened at $21.80 on Wednesday. Avantor, Inc. has a 1 year low of $18.41 and a 1 year high of $28.00. The stock has a market cap of $14.84 billion, a P/E ratio of 48.48, a price-to-earnings-growth ratio of 2.73 and a beta of 1.35. The firm has a 50-day moving average of $24.84 and a 200 day moving average of $24.08. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Barclays lowered their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. UBS Group reduced their price target on shares of Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, October 8th. Royal Bank of Canada restated an “outperform” rating and issued a $34.00 price target on shares of Avantor in a report on Thursday, September 26th. Stifel Nicolaus raised their price target on shares of Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, July 29th. Finally, Wells Fargo & Company reduced their price target on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, October 28th. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $27.57.

Insider Buying and Selling at Avantor

In other news, CAO Steven W. Eck sold 3,525 shares of Avantor stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the completion of the sale, the chief accounting officer now directly owns 29,544 shares in the company, valued at $740,372.64. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.50% of the stock is owned by company insiders.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.